The UK antitrust regulator has fined Pfizer roughly $14,000 for a “flagrant” violation of rules in connection with a probe into the pricing of an epilepsy medicine.
The move comes amid a heated squabble between Pfizer and the UK Competition and Markets Authority over phenytoin sodium capsules. The drug maker used to market the medicine under the brand name Epanutin, but sold the UK distribution rights to another company, Flynn Pharma, in 2012.
Pfizer continued to manufacture the drug, but prices began to rise significantly.
Pfizer suddenly began selling its medicine to Flynn at prices that were between eight and 17 times higher than what the company historically charged, according to the regulator. And Flynn sold the drug to customers at 25 and 27 times what Pfizer had been charging.
Full Content: Stat News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
Mar 18, 2025 by
CPI
BlackRock, Vanguard and State Street Seek Dismissal of Texas Antitrust Lawsuit
Mar 18, 2025 by
CPI
EU to Boost Metal Sectors with Energy Relief and Safeguards
Mar 18, 2025 by
CPI
Players’ Association Sues Tennis Governing Bodies Over Alleged Antitrust Violations
Mar 18, 2025 by
CPI
Turkey Moves to Curb Big Tech’s Power with New Regulatory Bill
Mar 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li